Sangamo BioSciences | SGMO - Loan Capital


Sangamo BioSciences reported $0 in Loan Capital for its fiscal quarter ending in June of 2022.





Loan Capital Change Date
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 50B 2.43B Dec/2025
Bayer EUR 31.83B 877M Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Cipla INR 2.98B 454.6M Sep/2025
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Grifols EUR 9.95B 722.93M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
J&J USD 39.44B 30M Dec/2025
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Merck USD 39.97B 6B Sep/2025
Novartis USD 29.59B 5.35B Dec/2025
Omeros USD 403.72M 27.2M Jun/2024
Pfizer USD 57.41B 93M Sep/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 15.72B 2.45B Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Tectonic Therapeutic USD 43K 57K Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025